Bretscher MT, et al. – Authors sought to quantify the relative benefit of long–acting or transmission–blocking drugs for reducing Plasmodium falciparum transmission to inform target product profiles in the drug development process and choice of first–line anti–malarial treatment in different endemic settings. Results suggested the importance of increasing access to treatment for routine case management, and the potential value of choosing first–line anti–malarial treatment policies according to local malaria epidemiology to maximise impact on transmission. As per observations, the optimal drug choice should not differ between delivery via case management or mass drug administration (MDA).